Qwest Corp 7 % Notes 2012-1.4.52 Called for red.on 04.09.18 at USD 25 (CTX)

0.00
NYSE
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 25.26 / 25.29
Exchange NYSE
Div & Yield N.A. (N.A)

Latest News

United States Patent And Trademark Office Issues U.S. Patent Covering An Enhanced Formulation Of Pliaglis®

United States Patent And Trademark Office Issues U.S. Patent Covering An Enhanced Formulation Of Pliaglis®

LAVAL, QC, July 16, 2019 /PRNewswire/ - Crescita Therapeutics Inc. ("Crescita" or the "Company") (TSX: CTX) (OTC US: CRRTF), a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the...

Crescita Therapeutics To Host Investor Webcast On July 24, 2019

Crescita Therapeutics To Host Investor Webcast On July 24, 2019

LAVAL, QC, July 11, 2019 /PRNewswire/ - Crescita Therapeutics Inc. ("Crescita" or the "Company") (TSX: CTX) (OTC US: CRRTF), a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the...

Crescita Therapeutics Inc. Receives 2nd Instalment Of Up-Front Payment Of €1.25 Million Following First Commercial Sale Of Pliaglis By Cantabria In Italy

Crescita Therapeutics Inc. Receives 2nd Instalment Of Up-Front Payment Of €1.25 Million Following First Commercial Sale Of Pliaglis By Cantabria In Italy

LAVAL, QC, July 4, 2019 /PRNewswire/ - Crescita Therapeutics Inc. ("Crescita" or the "Company") (TSX: CTX) (OTC US: CRRTF), a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the...

Crescita Therapeutics Inc. Announces Intention To Make Normal Course Issuer Bid

Crescita Therapeutics Inc. Announces Intention To Make Normal Course Issuer Bid

LAVAL, QC, June 17, 2019 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (" Crescita" or the " Company"), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products...

Crescita To Present At The 9th Annual LD Micro Invitational In Los Angeles, California

Crescita To Present At The 9th Annual LD Micro Invitational In Los Angeles, California

LAVAL, QC, May 30, 2019 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (Crescita or the Company), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the...

Crescita Therapeutics Engages Bristol Capital To Provide Investor Relations And Communications Services

Crescita Therapeutics Engages Bristol Capital To Provide Investor Relations And Communications Services

LAVAL, QC, May 29, 2019 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (Crescita or the Company), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the...

Crescita Therapeutics Announces The Results Of Its Annual General And Special Meeting Of Shareholders

Crescita Therapeutics Announces The Results Of Its Annual General And Special Meeting Of Shareholders

LAVAL, QC, May 15, 2019 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (Crescita or the Company), a commercial dermatology company with a portfolio of non-prescription skincare and prescription drug products for the treatment and...

Crescita Therapeutics Reports 2019 First Quarter Results

Crescita Therapeutics Reports 2019 First Quarter Results

Year-over-Year Revenue Growth of 16.4%Positive Adjusted EBITDA for Third Consecutive Quarter And Generates $2.

Crescita Therapeutics Strengthens Leadership Team With New Vice-President In Aesthetic And Cosmeceutical Business Unit

Crescita Therapeutics Strengthens Leadership Team With New Vice-President In Aesthetic And Cosmeceutical Business Unit

LAVAL, QC, May 7, 2019 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (Crescita or the Company), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the...

Crescita Therapeutics Signs Pliaglis® Out-Licensing Agreement With Cantabria Labs For €2.5M Upfront After Reacquiring Rest-of-World Rights

Crescita Therapeutics Signs Pliaglis® Out-Licensing Agreement With Cantabria Labs For €2.5M Upfront After Reacquiring Rest-of-World Rights

LAVAL, QC, April 25, 2019 /PRNewswire/ - Crescita Therapeutics Inc. ("Crescita" or the "Company") (TSX: CTX and OTC US: CRRTF), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products...

PulteGroup 3Q Loss Widens On Charges, Tops Street

Homebuilder PulteGroup's 3rd-quarter loss widens on charges, new orders drop 12 percent

Standard & Poor's Lowers Ratings On PulteGroup

Standard & Poor's Lowers Ratings On PulteGroup

S&P lowers ratings on homebuilder PulteGroup, sees weak earnings into 2011 on soft home sales

Homebuilder PulteGroup Returns To Profit In 2Q

Homebuilder PulteGroup posts profit in 2nd quarter ahead of expiration of tax credits

Earnings Preview: PulteGroup

Homebuilder PulteGroup expected to post a penny loss in 2nd-qtr

Pulte Pares 1Q Loss And Now Expects Profit In 2010

Pulte posts narrower loss on smaller charges, expects to report a profit in 2010

Earnings Preview: PulteGroup

Homebuilder PulteGroup expected to report loss for first quarter

PulteGroup CEO's '09 Compensation Essentially Flat

CEO of homebuilder PulteGroup received 2009 pay valued at $5.86 million, flat versus 2008

Housing Data Points To Rocky Rebound

Housing Data Points To Rocky Rebound

Home sales up, but housing recovery likely to be rocky, uneven

Weak Home Building A Drag On Economic Recovery

Weak Home Building A Drag On Economic Recovery

Weak home construction weighing down economic rebound; consumer inflation remains tame

Looking For Land In All The Right Places

Looking For Land In All The Right Places

Land market heats up again as homebuilders vie for property in promising markets

Pulte Homes, Merck, Garmin Are Big Movers

Pulte Homes, Merck, Garmin, Kraft, Ambac Financial are among big market movers Wednesday

Earnings Roundup: Pulte Homes, Ameristar Casinos

Earnings Roundup: Pulte Homes, Ameristar Casinos

Earnings roundup: Pulte Homes posts loss, but new orders rise; Ameristar Casinos profit rises

Pulte Homes Posts $361.4M Loss For Q3

Pulte Homes Posts $361.4M Loss For Q3

Homebuilder Pulte Homes loses $361.4 million in 3rd-qtr following Centex acquisition

Earnings Preview: Pulte Homes To Post 3Q Results

Homebuilder Pulte Homes to post 3rd-quarter results ahead of tax credit expiration

Homebuilder Shares Slide As Analyst Cuts Estimates

Homebuilder Shares Slide As Analyst Cuts Estimates

Shares of homebuilders slide as analyst cuts estimates, expects housing market to remain weak

Pulte Buys Back $1.5 Billion In Debt

Pulte Buys Back $1.5 Billion In Debt

Pulte buys back $1.5 billion in debt from Centex deal

Pulte Announces Early Tender Offer Results

Pulte Announces Early Tender Offer Results

Pulte announces early tender offer results for $1.5 billion in debt

Fitch Upgrades Centex Ratings In Line With Pulte's

Fitch Upgrades Centex Ratings In Line With Pulte's

Fitch upgrades Centex ratings in line with those at Pulte, which closed purchase of Centex